Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis
Authors:
- Ronald L. GibsonRGRonald L. Gibson
- Julia EmersonJEJulia Emerson
- Sharon McNamaraSMSharon McNamara
- Jane L. BurnsJBJane L. Burns
- Margaret RosenfeldMRMargaret Rosenfeld
- Ann YunkerAYAnn Yunker
- Nicole HamblettNHNicole Hamblett
- Frank AccursoFAFrank Accurso
- Mark DoveyMDMark Dovey
- Peter HiattPHPeter Hiatt
- Michael W. KonstanMKMichael W. Konstan
- Richard MossRMRichard Moss
- 15 March 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 167 (6) , 841-849
Abstract
We conducted a double-blind, placebo-controlled, multicenter, randomized trial to test the hypothesis that 300 mg of tobramycin solution for inhalation administered twice daily for 28 days would be safe and result in a profound decrease in Pseudomonas aeruginosa (Pa) density from the lower airway of young children with cystic fibrosis. Ninety-eight subjects were to be randomized; however, the trial was stopped early because of evidence of a significant microbiological treatment effect. Twenty-one children under age 6 years were randomized (8 active; 13 placebo) and underwent bronchoalveolar lavage at baseline and on Day 28. There was a significant difference between treatment groups in the reduction in Pa density; no Pa was detected on Day 28 in 8 of 8 active group patients compared with 1 of 13 placebo group patients. We observed no differences between treatment groups for clinical indices, markers of inflammation, or incidence of adverse events. No abnormalities in serum creatinine or audiometry and no episodes of significant bronchospasm were observed in association with active treatment. We conclude that 28 days of tobramycin solution for inhalation of 300 mg twice daily is safe and effective for significant reduction of lower airway Pa density in young children with cystic fibrosis.Keywords
This publication has 46 references indexed in Scilit:
- Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosisPediatric Pulmonology, 2002
- A resistance switchNature, 2002
- Use of Random Amplified Polymorphic DNA PCR To Examine Epidemiology of Stenotrophomonas maltophilia and Achromobacter ( Alcaligenes ) xylosoxidans from Patients with Cystic FibrosisJournal of Clinical Microbiology, 2001
- Longitudinal Assessment ofPseudomonas aeruginosain Young Children with Cystic FibrosisThe Journal of Infectious Diseases, 2001
- Aerosolized Antibiotics for Bacterial Lower Airway InfectionsClinical Pulmonary Medicine, 1997
- Nasal and Bronchoalveolar Lavage Fluid Cytokines in Early Cystic FibrosisThe Journal of Infectious Diseases, 1997
- Susceptibility of bacterial biofilms to tobramycin: role of specific growth rate and phase in the division cycleJournal of Antimicrobial Chemotherapy, 1990
- The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputumJournal of Antimicrobial Chemotherapy, 1988
- Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosisThe Journal of Pediatrics, 1988
- Clinical Application of Visual Reinforcement AudiometrySeminars in Hearing, 1984